Background-Although drug-eluting stents and intensive secondary prevention have contributed to improved outcomes after percutaneous coronary intervention (PCI), repeat revascularization remains relatively common in contemporary practice. We used data from the multicenter Evaluation of Drug-Eluting Stents and Ischemic Events registry to evaluate the relative frequency and timing of staged revascularization, target lesion revascularization (TLR), and other nontarget revascularization during the first year after contemporary PCI. Methods and Results-Patients with staged revascularization, TLR, and other unplanned procedures (elsewhere in the target vessel or in other coronary arteries) were evaluated in time-dependent models using Kaplan-Meier life-table estimation.
I n the early era of percutaneous coronary intervention (PCI) using bare metal stents, restenosis was the most common reason for repeat procedures during the first year after PCI, whereas treatment of nontarget lesions was considerably more common during later follow-up. 1 The introduction of drug-eluting stents (DES) has led to substantial reductions in restenosis and target lesion revascularization (TLR) after PCI. 2 These improvements have led interventional cardiologists to treat increasingly complex coronary anatomy, including frequent PCI in patients with off-label clinical scenarios, 3, 4 many of which are associated with higher rates of subsequent revascularization than those reported in randomized trials. [5] [6] [7] [8] In addition, despite increased attention to more intensive medical therapy for patients with established coronary artery disease (CAD), progressive atherosclerosis in sites unrelated to the revascularized segment commonly contributes to the need for repeat revascularization. 1, [9] [10] [11] [12] [13] 
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As a result of these temporal changes in disease management, repeat revascularization remains common in the first several years after PCI, even after accounting for widespread DES use in contemporary practice. 14 Whether these events reflect progression of atherosclerosis or unrecognized ischemia at originally untreated sites, staging of complex PCI procedures, or complications arising from the drug-eluting stent itself (ie, restenosis or stent thrombosis [ST]) is not known. To address this question, we used data from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry to evaluate the frequency, predictors, and timing of repeat revascularization, both planned and unplanned, during the first year after contemporary PCI.
Methods

Study Population
EVENT is a prospective observational registry designed to study PCI use in broad clinical practice at 55 US centers. 15 To minimize selection bias, unselected patients with intended stent implantation were enrolled; the only exclusion criteria were PCI or coronary artery bypass grafting (CABG) in the prior 4 weeks, implantation of an investigational or blinded device, or previous enrollment in EVENT. Demographic, clinical, and treatment variables were collected on standardized case-report forms in conjunction with detailed descriptions of angiographic characteristics and medication use before, during, and after PCI. Study site coordinators also recorded significant clinical events that occurred during the index hospitalization, including repeat revascularization, myocardial infarction (MI), and death. Patients or referring physicians were contacted by telephone at 6 and 12 months after PCI to determine whether any of these same events occurred after hospital discharge, and primary data were obtained whenever possible to allow detailed review of each event. Site investigators were required to complete a brief narrative describing each subsequent revascularization. All data were deidentified and submitted to the Harvard Clinical Research Institute for management. The human studies committee at each participating institution approved the study protocol, and written consent was obtained for each subject.
End Point Definitions
Individual narratives were reviewed by experienced clinical cardiologists (J.M.S., J.B.L., D.J.C.), and all repeat revascularization procedures were adjudicated by reviewing case-report forms and contacting the enrolling center for additional data when necessary. The study flow and modalities of revascularization are illustrated in Figure 1 . Stent thrombosis (ST) was present when an event met the Academic Research Consortium definition of definite ST. 16 TLR was defined as repeat PCI or bypass graft placement for restenosis at the lesion treated during index PCI or occurring within 5 mm of the PCI site (edge effect) as determined clinically by the investigator at each site. For the purposes of this analysis, repeat revascularization procedures because of ST were evaluated separately and, thus, not considered TLR events. Target vessel revascularization (TVR) was defined as unplanned repeat PCI or bypass graft placement for a stenosis in another part of the vessel treated at the index PCI (ie, exclusive of TLR events). Other vessel revascularization was defined as unplanned repeat revascularization of a coronary artery or bypass graft other than the vessel treated at index PCI. All PCI or CABG procedures that were planned to occur after completion of the index PCI were considered staged revascularization procedures. This designation was prospectively defined in the EVENT registry, and separate data collection procedures were employed for staged PCI after the index PCI procedure. 15
Analytic Approach
To evaluate the proportion and timing of different types of revascularization events, patients undergoing each modality of repeat revascularization were compared with patients who did not experience repeat revascularization. Time-to-event curves were constructed for each end point to identify the temporal distinctions between each type of repeat revascularization, and instantaneous hazard estimates were calculated using Kaplan-Meier life-table estimation. 17 Patients with missing follow-up data or those who died during follow-up (without first experiencing a repeat revascularization event) were censored at the time of last known contact. To avoid counting multiple unplanned revascularization events for an individual patient, end points other than staged PCI or CABG were evaluated in hierarchical fashion, such that unplanned revascularization events during follow-up were classified in the following rank order: (1) ST; (2) TLR; (3) TVR; and (4) other vessel revascularization. For example, a patient who experienced both ST and revascularization of another vessel (regardless of the timing of each event) would be designated as having ST and would be censored from further follow-up after ST in all time-toevent analyses. Furthermore, as sensitivity analyses, all time-to-event curves were repeated after accounting for competing events, which could potentially affect either the proportion or the timing of different repeat revascularization procedures. Specifically, these curves were repeated after multivariable adjustment, when using time-to-first event instead of the hierarchical end point, and after accounting for late MI (after hospital discharge) as a competing event.
To evaluate the role of staged revascularization in contemporary interventional practice, we first identified all patients who underwent planned multivessel revascularization in EVENT (ie, staged PCI or CABG, plus multivessel PCI at the index PCI procedure). We then compared clinical and angiographic characteristics of patients who underwent staged revascularization with those undergoing multivessel PCI during the index procedure. To quantify hospital-level variation in multivessel disease management, we constructed a hierarchical logistic regression model, with site as a random effect, to calculate the median odds ratio for performing staged revascularization procedures among all multivessel revascularization patients. The median odds ratio describes the median likelihood that a single patient with multivessel disease requiring revascularization, if presenting to 2 randomly selected hospitals in our study, would undergo staged revascularization at 1 hospital as compared with the other hospital. In order to avoid statistical biases among centers with low enrollment, only hospitals treating ≥20 patients with multivessel disease were evaluated in this particular analysis.
To compare the risk factors associated with restenosis-related versus nontarget repeat revascularization, we identified independent
WHAT IS KNOWN
• Restenosis and target lesion revascularization (TLR) occur less frequently since the introduction of drug-eluting stents.
• Nonetheless, repeat revascularization remains common after contemporary percutaneous coronary intervention (PCI).
• It remains unclear whether these repeat events represent TLR, staging of complex PCI procedures, or progressive atherosclerosis or unrecognized ischemia at previously untreated sites.
WHAT THE STUDY ADDS
• In a large multicenter registry of contemporary PCI, repeat revascularization occurred in ≈12% of patients within 1 year.
• One fourth of these repeat procedures were staged or planned, generally occurring within the first 1 to 2 months after PCI, and there was significant variability in multivessel disease management between hospitals.
• The remaining 9% of repeat procedures were unplanned, with half involving TLR and half involving nontarget revascularization, and predictors of these 2 subgroups of repeat revascularization were remarkably different.
• The low early hazard for stent thrombosis decreases even further after the first month.
• These findings suggest that future efforts should concentrate as much on identifying ischemiaproducing lesions and intensifying secondary prevention therapies as on the prevention of restenosis. predictors of TLR (excluding patients with ST) using hierarchical proportional hazards regression with stepwise selection, adjusting for enrolling hospital site in the hierarchical model. We then repeated this analysis to identify predictors of unplanned revascularization at nontarget sites (TVR plus other vessel revascularization). Candidate variables were those with nominal statistical significance in bivariate analysis (at P<0.1 level of significance) or established predictors of repeat revascularization from prior studies and included sociodemographic factors (age, sex, body-mass index, and tobacco use); clinical factors (hypertension, diabetes mellitus, hyperlipidemia, prior MI, prior PCI, prior CABG, heart failure, peripheral arterial disease, indication for PCI, and glomerular filtration rate); medications at hospital discharge after index PCI (aspirin, warfarin, statin, β-blocker, other lipid-lowering agent, calcium channel blocker, nitrate, angiotensin converting enzyme inhibitor, and angiotensin receptor blocker); and patient-level angiographic characteristics (number of diseased vessels, PCI vessel location, number of lesions undergoing PCI, bifurcation location, in-stent restenosis of the index lesion, Thrombolysis In Myocardial Infarction (TIMI) flow grade before PCI, lesion severity classification (A, B, or C), presence of visible thrombus before PCI, maximal lesion stenosis, total stent number, minimum stent diameter, total stent length, DES placement at index PCI, and DES stent type).
Continuous variables are described as mean±SD, and categorical variables are described as proportions. Bivariate comparisons were performed using χ 2 for categorical variables, t test for continuous variables, and nonparametric tests for variables without normal distributions, as appropriate. Results from multivariable analyses are described as odds ratios or hazard ratios with associated 95% confidence intervals. All analyses were performed with SAS software (version 8.2, SAS Institute, Cary, NC) and P values ≤0.05 were considered statistically significant unless otherwise specified.
Results
Between August 2004 and December 2007, the EVENT investigators enrolled 10 144 subjects of whom 43% were treated for an acute coronary syndrome, 86% were treated with at least 1 DES, and 30% underwent PCI of ≥2 lesions at the index PCI. An average of 1.6 stents (in 1.4 lesions) per patient were placed at the index procedure. During the 1-year follow-up, 1 or more repeat revascularization procedures were performed in 1207 patients (11.9%) overall, including staged procedures in 300 patients (2.9%), unplanned revascularization events in 907 patients (8.9%), and both staged and unplanned procedures in 17 patients (0.2%) ( Figure 1 ). Of the unplanned repeat procedures, approximately half were related to revascularization of the index lesion and half were at other nontarget sites ( Figure 2 ).
Timing of Repeat Procedures
Time-to-event curves and instantaneous hazard rates for each type of repeat revascularization are illustrated in Figure 3 . The overwhelming majority of events within the first 30 days were staged procedures, as unplanned events occurred at very low rates during the first month after index PCI. Between 1 and 12 months after PCI, the incidence of other vessel revascularization was relatively constant over time, ultimately accounting for slightly fewer cumulative events (2.8%) than TLR (3.9%) or staged procedures (3.1%) in the overall EVENT population by the end of 1 year. However, a more rapid increase in TLR was observed between 2 and Figure 1. Schematic of patient flow and data analyses. The first analysis reports cumulative incidence curves of each subtype of repeat revascularization, and the curves are then superimposed on 1 graph. The second analysis compares multivessel percutaneous coronary intervention (PCI) at the index procedure with staged revascularization, after which hospital-level variability in multivessel disease management is measured. The third analysis identifies predictors of target lesion and nontarget revascularization events. TLR indicates target lesion revascularization; TVR, target vessel revascularization. 9 months after PCI with a subsequent decrease in TLR rates during months 9 to 12, resulting in TLR rates during these last 3 months of follow-up, which were similar to the rates of other vessel revascularization. Findings were remarkably similar in the sensitivity analyses using adjusted cumulative incidence curves, with minimally lower 1-year revascularization rates because of the presence of MI as a competing event.
Staged Procedures
Staged revascularization by either PCI or CABG was performed in 293 (2.9%) and 24 (0.2%) patients, respectively. The median time to the staged procedure was 7 days (interquartile range, 2-28 days). Approximately 1 in 6 staged procedures was performed after initial PCI for ST-elevation MI. When compared with patients undergoing multivessel PCI at the index procedure (Table 1) , patients undergoing staged revascularization for multivessel disease were less likely to have established cardiovascular risk factors or prior PCI, but these individuals had worse angina, worse left ventricular function, and were more likely to have impaired coronary flow and greater intracoronary thrombus burden. Renal function was similar between patients with staged procedures versus those undergoing multivessel PCI at enrollment. Practice patterns varied significantly between hospitals, as the frequency of staged PCI or CABG among patients requiring multivessel revascularization ranged from 0% to >50% across the different hospitals that enrolled at least 20 patients in EVENT (Figure 4 ). The median odds ratio for undergoing staged revascularization was 2.2 (P<0.001 for random effects), suggesting more than a 2-fold difference in the median likelihood of undergoing staged revascularization (versus multivessel intervention at index PCI) among patients requiring multivessel revascularization if they were treated at 2 randomly selected hospitals in EVENT.
Unplanned Revascularization
Of the 907 patients undergoing unplanned revascularization within the first year, patients who experienced TLR were younger, more likely to be female, had more baseline angina, and had more atherosclerotic risk factors and established coronary disease than patients without repeat revascularization ( Table 2 ). There were no differences in the indication for PCI or objective laboratory findings, but these individuals also had more complex coronary lesions, higher rates of PCI for prior in-stent restenosis, greater stent lengths, and smaller stent diameters when compared with patients who did not undergo repeat revascularization. Lower rates of drug-eluting stent use were also associated with subsequent TLR, with no significant difference in TLR rates between sirolimus-eluting and paclitaxel-eluting stents (4.5% versus 3.8%; P=0.11). In contrast, patients experiencing nontarget events (TVR plus other vessel revascularization) had similar baseline characteristics as those without repeat revascularization during follow-up, with virtually none of the angiographic or stent characteristics noted to be associated with TLR ( Table 2 ).
Predictors of Unplanned Revascularization
Predictors of TLR are contrasted with predictors of nontarget revascularization events in Figure 5 . After multivariable adjustment, TLR predictors included a variety of demographic (age and sex), clinical (smoking status, prior MI, and prior PCI), and angiographic characteristics (PCI of the left main or saphenous vein graft, total stent length, minimum stent diameter, and use of a drug-eluting stent). In contrast, substantially fewer predictors of unplanned nontarget revascularization were identified (age, number of diseased coronary arteries, and vein graft PCI). 
Discussion
Despite high rates of DES use among patients undergoing contemporary PCI, our analysis from a large, prospectively-obtained, broadly-representative PCI registry demonstrates that repeat revascularization is performed in ≈12% of individuals by 1 year of follow-up. To our knowledge, this is the first analysis of repeat revascularization among unselected patients that evaluates individually the timing of different types of repeat procedures and also highlights the high frequency of staged revascularization after contemporary PCI. We found that ≈one fourth of repeat procedures were planned at the time of index PCI, and the vast majority of these staged procedures were performed within 1 to 2 months. In addition, given the variability in use of staged revascularization between hospitals in EVENT, hospital-level practice patterns appear to play an important role in the management of multivessel CAD. Among the ≈9% of patients requiring unplanned repeat revascularization, several important findings should be highlighted. First, only half of these unplanned events are related to repeat intervention at the site of index PCI, whereas the other half are related to revascularization at nontarget sites, perhaps representing unrecognized ischemia-producing lesions or progressive atherosclerosis in other locations. Second, time-dependent analyses confirmed the low early hazard of ST (which decreases further after the first month), and the preponderance of TLR events between months 2 to 9 after PCI, after which the risks of TLR versus other nontarget events are remarkably similar. Third, the predictors of TLR identified in this real-world observational registry include many clinical and angiographic variables traditionally related to restenosis. In contrast, predictors of nontarget lesion revascularization at locations distant from the initial PCI lesion are difficult to identify, possibly reflecting the 1-year follow-up in EVENT which inadequately captures the impact of longstanding risk factors or intensity of therapy for chronic atherosclerotic disease. Furthermore, some of these nontarget lesion procedures during follow-up may reflect late identification of ischemia-producing lesions which were not recognized at the index PCI.
Staged Revascularization
The majority of studies evaluating staged revascularization focus specifically on patients with multivessel coronary disease experiencing ST-elevation MI. [18] [19] [20] [21] In contrast, we observed that only 1 in 6 of these staged procedures is performed in patients with ST-segment elevation MI, with the rest performed in more elective settings. Nonetheless, the acuity of patients who underwent staged PCI in EVENT was higher than that of patients who underwent initial multivessel PCI, with more acute coronary syndromes and worse coronary lesion characteristics than patients undergoing initial multivessel PCI. It is likely that staging of these procedures reflects the high degree of coronary and patient complexity being treated in contemporary PCI practice, 4 including the need for careful evaluation of therapeutic options or medical stabilization and application of adjunctive therapies such as ventricular support devices. 22 However, given the high degree of hospitallevel variability in multivessel disease management noted in our analysis, it appears that local practice patterns may be an important driver of the decisions surrounding staging of procedures as well.
Prior Studies of Unplanned Revascularization
Several clinical trials of coronary revascularization have indicated that ongoing atherosclerotic disease activity confounds the interpretation of clinical efficacy of therapies directed at reducing restenosis. 1, 9, 13, 23, 24 For example, both Chacko et al 23 and Leon et al 24 reported long-term follow-up from the pivotal early randomized trials of DES. Both sirolimus-eluting and paclitaxel-eluting DES significantly reduced TLR when compared with bare metal stents (BMS). However, in both analyses there were no differences between DES and BMS in terms of remote TVR or other vessel revascularization events, particularly after the first year of follow-up. Furthermore, these nonstent-related events were remarkably common, as remote TVR events remained constant (≈2% per year, with cumulative rates of 12%-15%) and other vessel revascularization events occurred in >25% of patients by 5 years of follow-up, despite persistent reductions in TLR events with DES. Similar findings have been described in observational studies of patients with diabetes mellitus, 12, 25 with recent ST-elevation MI, 11 or among patients undergoing PCI before the DES era. 10, 12 All of these studies of unselected patients outside of randomized trials confirm high rates of disease progression in nontarget lesions and vessels, ultimately accounting for 42%-57% of the repeat procedures during the year after index PCI.
Our study reinforces these findings by demonstrating equivalent rates of target lesion events and nontarget lesion repeat revascularization within the first year after PCI among unselected patients treated in the DES era. Furthermore, rates of non-TLR unplanned intervention have only decreased from ≈6% in the late 1990s 10 to ≈4.5% in our contemporary patient population in the DES era. Thus, despite increasingly aggressive medical therapy for secondary prevention of CAD, 26, 27 our findings suggest that only modest improvements in reducing short-term atherosclerotic progression have been achieved, at least in terms of the impact on subsequent revascularization of nontarget coronary lesions. Part of this persistent need for nontarget revascularization may stem from wire trauma or adverse effects from first-generation DES on the downstream vessel, thus increasing rates of TVR, and some events may occur as a result of unrecognized ischemia-producing stenoses in both the target vessel and in nontarget vessels (as discussed earlier). As suggested by some investigators, future studies should investigate the role of more aggressive surveillance for atherosclerotic progression and even more intensive or novel antiatherosclerotic therapies to help reduce the incidence of disease progression in patients undergoing coronary revascularization. [26] [27] [28] [29] [30] [31] [32] In addition, better attention to revascularizing ischemia-producing lesions (identified more aggressively using either noninvasive or invasive techniques, such as fractional flow reserve) may help reduce rates of nontarget repeat revascularization, as suggested by recent clinical trials. 33 These approaches are important even within the context of contemporary PCI clinical trials, as unrecognized ischemiaproducing lesions and progressive coronary disease at distant coronary sites appear to be as important as stent selection and optimization of therapy at the target lesion, thus affecting the choice of clinical end points in these trials.
Study Limitations
Our study should be interpreted in the context of several important limitations. First, this post hoc analysis of EVENT is subject to all the limitations inherent in observational registries, including the determination of TLR and ST at the discretion of study site investigators rather than a clinical events committee. Unfortunately, data regarding the underlying complexity of CAD at diagnostic catheterization, which may further stratify risk among patients undergoing PCI, were not collected in EVENT. Nonetheless, all clinical events were independently reviewed by experienced clinical cardiologists for classification, and the use of real-world determination of the revascularization subtypes likely renders our findings more generalizable to routine clinical practice. Second, the use of 1-year follow-up could affect the proportions of events related to different reasons for repeat revascularization, when compared with studies incorporating longer term follow-up. Third, our analysis probably underestimated the burden of repeat revascularization by limiting the analysis to a single, hierarchically selected repeat procedure. In addition, the hierarchical nature of our end point may have overestimated the contribution of events related to the target lesion (ST and TLR), which occur somewhat earlier than nontarget revascularization related to atherosclerotic progression. Thus, the burden of repeat revascularization related to CAD progression at distant coronary sites is likely to be even higher than noted in our analysis. Lastly, patients lost to follow-up could not be evaluated for repeat revascularization procedures, although the vital status and subsequent follow-up in EVENT was available in ≈95% of patients.
Conclusions
Despite increasingly complex patients and lesions treated by contemporary PCI, overall repeat revascularization rates remain around 12% at 1 year, and more than one fourth of these repeat procedures are staged interventions related to multivessel CAD. In addition, only half of the unplanned repeat revascularizations are performed for clinically relevant restenosis, with ongoing rates of nontarget lesion revascularization that remain consistent and are only mildly improved from the pre-DES era. These findings highlight the importance of identifying ischemiaproducing stenoses accurately and ascertaining that appropriate secondary prevention therapies are implemented after PCI, as the clinical relevance of restenosis prevention has lessened in the DES era. Given the preponderance of non-TLR events in current practice, future studies should evaluate all causes of repeat revascularization, including those outside of the target lesion or target vessel, to help improve the outcomes of patients with coronary disease requiring treatment with PCI.
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